Abacus Life, Inc. Form 8-K Summary
Business Context and Reporting Period
Date: July 18, 2024
Company: Abacus Life, Inc. (Ticker: ABL)
Event: Entry into a Material Definitive Agreement (Share Purchase Agreement).
Context: Abacus Life, Inc. announced the acquisition of Carlisle Management Company S.C.A. (CMC) and Carlisle Investment Group S.A.R.L. (CIG), collectively referred to as the "Companies." The target entities are a Luxembourg-based investment manager operating in the life settlement space.
Key Financial Metrics and Transaction Structure
Transaction Value: Approximately $200 million (Base Purchase Price, subject to customary adjustments).
Consideration Mix:
- Equity: 62.3% of the purchase price in newly issued Abacus common stock. Valued at $13.05 per share. This issuance is capped at 19.9% of Abacus's outstanding shares pre-issuance.
- Debt: 37.7% of the purchase price in newly issued fixed-rate senior notes. These notes mirror Abacus's existing 9.875% Fixed Rate Senior Notes due 2028 regarding seniority, redemption, and interest.
Escrow: 10% of the Base Purchase Price (split between stock and bond consideration) will be held in escrow for 18 months to cover purchase price adjustments and indemnification obligations.
Financial Performance: The filing does not provide specific revenue, profit, cash flow, or margin data for Abacus or the target companies. It notes a closing condition requiring the Companies' estimated annualized base management fee to meet an agreed target, but the specific target value is not disclosed.
Material Changes and Conditions
The transaction represents a significant expansion of Abacus's operations into the Luxembourg life settlement market. The closing is contingent upon several material conditions:
- Non-objection from the Commission de Surveillance du Secteur Financier (Luxembourg financial supervisory authority).
- Target Companies' cash at closing must be at least $4,755,398.
- Receipt of consents from the Companies' lenders and other relevant parties.
- Completion of a restructuring agreement among certain shareholders of the Companies.
- Absence of material adverse events for both Abacus and the Companies.
Outlook, Risks, and Unusual Items
Timeline: The agreement includes an "End Date" of April 18, 2025, which may be extended by 90 days if regulatory approvals are delayed.
Shareholder Restrictions: Seller stockholders are subject to lock-up agreements: 50% of received shares are locked until July 3, 2025, and the remaining 50% until January 3, 2026. A 12-month standstill restriction also applies.
Risks: The filing includes standard forward-looking statement disclaimers. Risks include failure to obtain regulatory approvals, failure to meet closing conditions (such as the cash or management fee targets), and potential material adverse events. The transaction is subject to termination if closing does not occur by the End Date or if representations and warranties are breached.
Investor Verification Checklist
- Verify the final purchase price adjustments and the exact number of shares and notes issued upon closing.
- Confirm the receipt of the non-objection from the Luxembourg financial supervisory authority.
- Monitor the Companies' cash position to ensure it meets the $4.76 million minimum at closing.
- Review the impact of the new debt issuance on Abacus's overall leverage and interest coverage ratios.
- Track the integration progress and the realization of the target management fee revenue.